跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 11 条关于
“Xolremdi”
全部
11
临床试验
0
药物
0
机构
0
资讯
11
2年前
FDA Approves XOLREMDI (mavorixafor) as First Targeted Therapy for WHIM Syndrome
去年
X4 Pharmaceuticals' Mavorixafor Shows Promise in Chronic Neutropenia Phase 2 Trial
去年
X4 Pharmaceuticals Announces Positive Phase 2 Results for Mavorixafor in Chronic Neutropenia
去年
FDA Approvals in 2024: Novel Therapies for MASH, WHIM Syndrome, Pediatric Glioma, MDS, and Bladder Cancer
10个月前
X4 Pharmaceuticals Secures $135 Million to Advance Mavorixafor Phase 3 Trials
去年
X4 Pharmaceuticals Secures $60 Million Financing and Installs New Leadership Team
7个月前
European Regulators Recommend Approval of First WHIM Syndrome Treatment
去年
EMA Validates Marketing Authorization Application for Mavorixafor in WHIM Syndrome Treatment
去年
FDA Approves Five Groundbreaking Treatments for Ultra-Rare Diseases in Recent Months
去年
X4 Pharmaceuticals Secures $85 Million Private Placement to Advance Mavorixafor Development
第 1 页,共 2 页
上一页
下一页